171 related articles for article (PubMed ID: 28797730)
1. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions.
Li Q; Liu Q; Huang W; Wu J; Nie J; Wang M; Zhao C; Zhang L; Wang Y
Vaccine; 2017 Sep; 35(38):5172-5178. PubMed ID: 28797730
[TBL] [Abstract][Full Text] [Related]
2. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
[TBL] [Abstract][Full Text] [Related]
3. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; MartÃnez-Sobrido L
mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
[TBL] [Abstract][Full Text] [Related]
4. Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever.
Wang M; Li R; Li Y; Yu C; Chi X; Wu S; Liu S; Xu J; Chen W
Viruses; 2021 Mar; 13(3):. PubMed ID: 33804206
[TBL] [Abstract][Full Text] [Related]
5. An mRNA-LNP-based Lassa virus vaccine induces protective immunity in mice.
Hashizume M; Takashima A; Iwasaki M
J Virol; 2024 Jun; 98(6):e0057824. PubMed ID: 38767352
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
[TBL] [Abstract][Full Text] [Related]
8. Current research for a vaccine against Lassa hemorrhagic fever virus.
Warner BM; Safronetz D; Stein DR
Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
[TBL] [Abstract][Full Text] [Related]
9. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
[TBL] [Abstract][Full Text] [Related]
10. Vaccine platforms to control Lassa fever.
Lukashevich IS; Pushko P
Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.
Goicochea MA; Zapata JC; Bryant J; Davis H; Salvato MS; Lukashevich IS
Vaccine; 2012 Feb; 30(8):1445-52. PubMed ID: 22234266
[TBL] [Abstract][Full Text] [Related]
12. Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system.
Wu J; Zhao C; Liu Q; Huang W; Wang Y
Vaccine; 2017 Nov; 35(47):6387-6394. PubMed ID: 29031692
[TBL] [Abstract][Full Text] [Related]
13. Identification of protective Lassa virus epitopes that are restricted by HLA-A2.
Botten J; Alexander J; Pasquetto V; Sidney J; Barrowman P; Ting J; Peters B; Southwood S; Stewart B; Rodriguez-Carreno MP; Mothe B; Whitton JL; Sette A; Buchmeier MJ
J Virol; 2006 Sep; 80(17):8351-61. PubMed ID: 16912286
[TBL] [Abstract][Full Text] [Related]
14. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
[TBL] [Abstract][Full Text] [Related]
15. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.
Cashman KA; Wilkinson ER; Shaia CI; Facemire PR; Bell TM; Bearss JJ; Shamblin JD; Wollen SE; Broderick KE; Sardesai NY; Schmaljohn CS
Hum Vaccin Immunother; 2017 Dec; 13(12):2902-2911. PubMed ID: 29045192
[TBL] [Abstract][Full Text] [Related]
16. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.
Ibukun FI
Viruses; 2020 Mar; 12(4):. PubMed ID: 32244402
[TBL] [Abstract][Full Text] [Related]
17. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
[TBL] [Abstract][Full Text] [Related]
18. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.
Fischer RJ; Purushotham JN; van Doremalen N; Sebastian S; Meade-White K; Cordova K; Letko M; Jeremiah Matson M; Feldmann F; Haddock E; LaCasse R; Saturday G; Lambe T; Gilbert SC; Munster VJ
NPJ Vaccines; 2021 Mar; 6(1):32. PubMed ID: 33654106
[TBL] [Abstract][Full Text] [Related]
19. Vaccine platforms for the prevention of Lassa fever.
Purushotham J; Lambe T; Gilbert SC
Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
[TBL] [Abstract][Full Text] [Related]
20. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
Hastie KM; Cross RW; Harkins SS; Zandonatti MA; Koval AP; Heinrich ML; Rowland MM; Robinson JE; Geisbert TW; Garry RF; Branco LM; Saphire EO
Cell; 2019 Aug; 178(4):1004-1015.e14. PubMed ID: 31398326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
